Dr. Christopher Moertel
Claim this profileUniversity of Minnesota/Masonic Cancer Center
Studies Neurofibromatosis
Studies Cerebral Gliomas
15 reported clinical trials
24 drugs studied
Area of expertise
1Neurofibromatosis
NF1 positive
NF2 positive
Stage IV
2Cerebral Gliomas
Stage IV
Stage I
Stage II
Affiliated Hospitals
Clinical Trials Christopher Moertel is currently running
REC-2282
for Meningioma
This trial is testing a new drug called REC-2282 to see if it can help treat specific brain tumors in patients who haven't responded to other treatments. The study will check if the drug can slow down or stop the growth of these tumors.
Recruiting0 awards Phase 2 & 35 criteria
Selumetinib + Vinblastine
for Low-Grade Glioma
This phase III trial investigates the best dose of vinblastine in combination with selumetinib and the benefit of adding vinblastine to selumetinib compared to selumetinib alone in treating children and young adults with low-grade glioma (a common type of brain cancer) that has come back after prior treatment (recurrent) or does not respond to therapy (progressive). Selumetinib is a drug that works by blocking a protein that lets tumor cells grow without stopping. Vinblastine blocks cell growth by stopping cell division and may kill cancer cells. Giving selumetinib in combination with vinblastine may work better than selumetinib alone in treating recurrent or progressive low-grade glioma.
Recruiting2 awards Phase 339 criteria
More about Christopher Moertel
Clinical Trial Related5 years of experience running clinical trials · Led 15 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Christopher Moertel has experience with
- Selumetinib
- Radiation Therapy
- Curcumin
- High Phenolic Extra Virgin Olive Oil (HP-EVOO)
- Mirdametinib (PD-0325901)
- Placebo
Breakdown of trials Christopher Moertel has run
Neurofibromatosis
Cerebral Gliomas
Neurofibroma
Fibrillary Astrocytoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Christopher Moertel specialize in?
Christopher Moertel focuses on Neurofibromatosis and Cerebral Gliomas. In particular, much of their work with Neurofibromatosis has involved NF1 positive patients, or patients who are NF2 positive.
Is Christopher Moertel currently recruiting for clinical trials?
Yes, Christopher Moertel is currently recruiting for 4 clinical trials in Minneapolis Minnesota. If you're interested in participating, you should apply.
Are there any treatments that Christopher Moertel has studied deeply?
Yes, Christopher Moertel has studied treatments such as Selumetinib, Radiation Therapy, curcumin.
What is the best way to schedule an appointment with Christopher Moertel?
Apply for one of the trials that Christopher Moertel is conducting.
What is the office address of Christopher Moertel?
The office of Christopher Moertel is located at: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota 55455 United States. This is the address for their practice at the University of Minnesota/Masonic Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.